How to Get Zepbound in District of Columbia

What Is Zepbound and Why DC Residents Are Asking About It

Zepbound is the brand name for tirzepatide 2.5 mg to 15 mg subcutaneous injection, approved by the FDA in May 2024 for chronic weight management in adults with obesity or overweight plus at least one weight-related condition. It is the first approved dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist for this indication. Review the Zepbound prescribing information on the FDA label.

The SURMOUNT-1 Trial: What the Evidence Shows

The key SURMOUNT-1 trial (N=2,539) published in the New England Journal of Medicine in 2022 randomized adults with a BMI ≥30 (or ≥27 with a weight-related comorbidity) to tirzepatide 5 mg, 10 mg, or 15 mg once weekly versus placebo for 72 weeks. Participants on the 15 mg dose achieved a mean weight reduction of 20.9% from baseline, compared with 3.1% in the placebo group (P<0.001). The 10 mg dose produced 19.5% mean weight loss, and the 5 mg dose produced 15.0%. Read the full SURMOUNT-1 results at NEJM.

These are not modest results. A 20.9% mean weight loss at the highest dose approaches outcomes historically seen only with bariatric surgery, and that fact has driven significant demand among DC residents seeking access.

FDA-Approved Indications and Eligible BMI Thresholds

The FDA approved Zepbound for adults who meet at least one of the following criteria:

• BMI ≥30 kg/m2 (classified as obesity)
• BMI ≥27 kg/m2 with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea

Prescribers in DC must document which criterion applies at the initial visit. This documentation also anchors the prior authorization process for insured patients.

Telehealth Prescribing for Zepbound in DC

DC permits telehealth prescribing of controlled and non-controlled medications, including Schedule III through V drugs and GLP-1/GIP receptor agonists such as tirzepatide. Zepbound is not a controlled substance, so there is no DEA-related telehealth restriction that applies here.

How a DC Telehealth Visit Works

A qualifying telehealth encounter for Zepbound follows this sequence:

1. Intake questionnaire. The patient submits height, weight, medical history, current medications, and recent lab work through the platform's secure portal.
2. Synchronous or asynchronous visit. DC law permits both live video visits and asynchronous (store-and-forward) encounters for weight-management prescribing, as long as the prescriber holds an active DC license.
3. Prescription issuance. The prescriber sends the Zepbound prescription electronically to a pharmacy of the patient's choice. Most DC telehealth platforms transmit to a mail-order or specialty pharmacy within 24 hours of approval.
4. Ongoing follow-up. Dose titration check-ins typically occur at weeks 4, 8, 12, and 20 via telehealth, matching the standard titration schedule in the SURMOUNT program.

The DC Department of Health does not require an in-person physical exam before a telehealth GLP-1 prescription is issued, which sets DC apart from some states that mandate an initial face-to-face visit. See the HHS Office for Civil Rights guidance on telehealth flexibilities.

Prescribers Who Can Write the Rx in DC

All of the following are authorized to prescribe Zepbound in the District of Columbia:

• Medical doctors (MD) and doctors of osteopathic medicine (DO)
• Nurse practitioners (NP) with prescriptive authority, which all DC NPs with a Collaborative Agreement or independent practice status hold
• Physician assistants (PA) who hold a current DC PA license with prescribing privileges

DC granted NPs full practice authority in 2022, meaning an NP does not require a physician's co-signature or oversight to prescribe tirzepatide. That change expanded telehealth access substantially for DC residents.

Lab Work Required Before and During Zepbound Treatment

Most DC prescribers order a standard metabolic panel before initiating tirzepatide. Getting labs done in advance speeds up the prescribing visit.

Pre-Treatment Labs

The following labs are typically required or strongly recommended:

• HbA1c to rule out undiagnosed type 2 diabetes and to establish a baseline
• Fasting glucose for the same reason
• Comprehensive metabolic panel (CMP) including liver enzymes, creatinine, and electrolytes
• Lipid panel (LDL, HDL, triglycerides)
• TSH to rule out thyroid pathology, given Zepbound's boxed warning regarding medullary thyroid carcinoma risk in patients with a personal or family history of MEN2 or MTC
• Complete blood count (CBC) at some clinician's discretion

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Clinicians should evaluate patients for contraindications and comorbidities before initiating GLP-1 receptor agonist therapy, including thyroid cancer history, pancreatitis history, and renal function." Access the Endocrine Society guidelines at endocrine.org.

On-Treatment Monitoring

After starting Zepbound, most DC clinicians recheck HbA1c and CMP at the 3-month and 6-month marks. Patients with pre-existing kidney disease may need creatinine monitored more frequently because tirzepatide-related nausea and reduced oral intake can temporarily lower eGFR through dehydration.

Getting a Zepbound Prescription in DC: Step-by-Step

Step 1: Confirm Eligibility

Check your BMI. At 5 feet 6 inches and 190 pounds, your BMI is approximately 30.7, which meets the obesity threshold without a comorbidity. At 185 pounds (BMI ~29.9), you would need to document a qualifying condition such as hypertension, type 2 diabetes, or sleep apnea.

Step 2: Choose Your Prescriber

Options in DC include:

• Endocrinologists and obesity medicine specialists at hospital systems such as MedStar Georgetown, George Washington University Hospital, and Howard University Hospital
• Primary care physicians who have integrated GLP-1 prescribing into their practice
• Telehealth platforms with DC-licensed prescribers, including HealthRX, which offers asynchronous or same-week video consultations

Step 3: Complete Your Visit and Labs

Bring (or upload) your most recent labs. If you do not have recent bloodwork, many DC telehealth platforms partner with Quest Diagnostics or LabCorp for same-week draw appointments across the District.

Step 4: Pharmacy and Fulfillment

Once the prescription is issued, you have several fulfillment paths:

• Lilly's manufacturer coupon program. Commercially insured patients may pay as little as $25 per month for Zepbound through the Lilly Savings Card, which applies to prescriptions at participating retail pharmacies.
• Specialty pharmacies. CVS Specialty, Walgreens Specialty, and several independent DC pharmacies stock Zepbound auto-injector pens.
• 503A compounding pharmacies. A 503A-licensed compounding pharmacy can prepare tirzepatide for a patient-specific prescription in DC. The FDA's shortage policy allowing compounding of tirzepatide has evolved; as of early 2025 the FDA has declared the tirzepatide shortage resolved, which affects whether compounded versions remain permissible. Patients should confirm current status with their prescriber. Check the FDA drug shortage database for the latest tirzepatide status.

Step 5: Titration and Follow-Up

The standard titration schedule for Zepbound begins at 2.5 mg once weekly for 4 weeks, then advances in 2.5 mg increments every 4 weeks as tolerated. Most patients reach a maintenance dose of 10 mg or 15 mg by approximately week 20. Telehealth follow-up visits at each titration step are billable under DC telehealth reimbursement rules.

DC Medicaid Coverage for Zepbound

DC Medicaid covers Zepbound for chronic weight management with prior authorization. This makes DC one of the more favorable coverage environments for low-income patients seeking GLP-1 access. CMS guidance on anti-obesity medication coverage is available at cms.gov.

Prior Authorization Requirements in DC Medicaid

To obtain prior authorization for Zepbound through DC Medicaid, the prescribing clinician typically must document:

• Confirmed BMI ≥30, or BMI ≥27 with a qualifying comorbidity (documented with ICD-10 code)
• At least one prior attempt at lifestyle modification (such as a structured diet program or documented counseling visits)
• Absence of contraindications (personal or family history of MTC or MEN2, active pancreatitis, pregnancy)
• A treatment plan including dietary and activity counseling

The American Association of Clinical Endocrinology (AACE) 2023 obesity algorithm specifies that pharmacotherapy is appropriate when lifestyle intervention alone has not achieved clinically meaningful weight loss (generally defined as less than 5% body weight reduction after 3 to 6 months of supervised effort). Read the AACE obesity guidelines at aace.com.

Private Insurance Prior Authorization

Commercial plans operating in DC (Anthem, Aetna, CareFirst BlueCross BlueShield, and United Healthcare) each have their own PA criteria for Zepbound. Most require:

• BMI documentation from a clinical encounter within the past 12 months
• A 90-day trial of lifestyle modification (some plans waive this with documented comorbidity)
• Step therapy through metformin or another agent for patients with type 2 diabetes

A 2023 JAMA Health Forum analysis found that among commercially insured patients, prior authorization approval rates for GLP-1 receptor agonists varied from 48% to 82% depending on plan type and submitted documentation quality. Submitting labs, visit notes, and BMI measurements simultaneously with the PA request reduces back-and-forth by an average of 6 days. See the JAMA Health Forum coverage data.

503A Compounding Pharmacies and Tirzepatide in DC

503A pharmacies are state-licensed compounding pharmacies that prepare medications for individual patients based on a valid prescription. In DC, 503A pharmacies may compound tirzepatide when a documented shortage exists at the FDA level.

The following framework helps DC patients and prescribers decide which fulfillment path to use:

Zepbound Access Decision Framework for DC Patients (HealthRX)

| Situation | Recommended Path | |---|---| | Commercially insured, PA approved | Brand Zepbound at participating retail or specialty pharmacy | | DC Medicaid, PA approved | Brand Zepbound at Medicaid-participating pharmacy | | Commercially insured, PA denied or pending | Appeal with additional documentation; Lilly coupon as bridge | | Self-pay, brand cost unaffordable | 503A compound (only while FDA shortage designation is active) | | Contraindication to brand excipients | 503A compound per prescriber clinical judgment |

Patients should be aware that compounded tirzepatide from a 503A pharmacy does not carry the same FDA oversight as the brand product. The inactive ingredients may differ, and potency verification depends entirely on the compounding pharmacy's internal quality protocols. Ask for a certificate of analysis before accepting a compounded product.

Transferring a Zepbound Prescription to DC

Patients who move to DC from another state or who have an existing Zepbound prescription from an out-of-state telehealth platform can transfer their prescription to a DC-based pharmacy without a new clinical visit, as long as the prescribing clinician holds licensure valid in DC (or in the originating state, if the telehealth platform operates under an interstate compact).

DC participates in the Interstate Medical Licensure Compact (IMLC), so physicians licensed through the compact may prescribe to DC residents without a separate DC license. NPs in DC may receive prescriptions transferred from out-of-state NPs as long as the originating prescription was lawfully issued.

To transfer, contact the receiving pharmacy directly with the prescription number and the name of the originating pharmacy. Transfers of Schedule II drugs are prohibited by federal law, but Zepbound is not scheduled, so no restriction applies here.

How Long Until You Receive Zepbound in DC

From the moment a prescription is sent to the pharmacy, typical wait times in DC break down as follows:

• Retail pharmacy (CVS, Walgreens, Safeway): 1 to 3 business days if in stock. Zepbound stock at DC retail locations has been inconsistent; calling ahead to confirm pen availability by dose is advisable.
• Mail-order specialty pharmacy: 3 to 7 business days for the first fill. Subsequent refills typically ship within 24 hours of order placement.
• 503A compounding pharmacy: 5 to 10 business days for the first compound, as some preparations are made to order.

Insurance prior authorization adds time. If your PA is submitted same-day as the visit, most DC commercial plans respond within 3 to 5 business days under DC insurance prompt-payment rules. Medicaid PA decisions are required within 3 business days for non-urgent requests under federal Medicaid managed care regulations. Review CMS Medicaid managed care timelines.

Side Effects DC Patients Should Know Before Starting

Tirzepatide's most common adverse effects, reported in SURMOUNT-1, were gastrointestinal: nausea (44.4% on 15 mg vs. 17.6% placebo), diarrhea (30.4% vs. 10.0%), vomiting (24.5% vs. 5.0%), and constipation (17.2% vs. 9.5%). Review the full adverse event data in the SURMOUNT-1 NEJM publication. Most GI symptoms peak during the first 4 to 8 weeks of each dose increase and then diminish.

DC prescribers commonly counsel patients to:

• Eat smaller, lower-fat meals during dose escalation
• Stay well-hydrated, especially during summer months in DC when ambient temperatures are high
• Avoid lying down within 2 hours of eating to reduce reflux symptoms
• Report any severe or persistent abdominal pain promptly, as pancreatitis is a rare but serious risk

Zepbound carries a boxed warning for thyroid C-cell tumors observed in rodent studies. While human relevance has not been established, the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). See the FDA boxed warning details in the Zepbound label.

Cost and Savings Programs for DC Patients

The list price of Zepbound is approximately $1,059 per month for a single-dose pen (4 pens per box for the 2.5 mg and 5 mg starter doses). For commercially insured patients with an active Lilly Savings Card, out-of-pocket cost may be reduced to $25 per 4-week supply for eligible plans.

Patients without insurance or with coverage gaps can explore:

• Lilly's income-based patient assistance program. Household incomes at or below 400% of the federal poverty level may qualify for free or reduced-cost Zepbound through Lilly Cares.
• DC Health Link marketplace plans. DC's ACA marketplace (DC Health Link) offers plans that may cover anti-obesity medications depending on the formulary. Open enrollment typically runs November through January.
• DC Medicaid (Healthy Families DC). As noted above, Zepbound is covered with PA for eligible beneficiaries.

The CDC reports that approximately 33.6% of DC adults have obesity (BMI ≥30), compared with a national average of 41.9%, though the District's rate masks significant geographic variation by ward. Review DC obesity prevalence data at the CDC BRFSS portal.